Cargando…

Azilsartan: Current Evidence and Perspectives in Management of Hypertension

Hypertension continues to be global pandemic with huge mortality, morbidity, and financial burden on the health system. Unfortunately, most patients with hypertension would eventually require two or more drugs in combination to achieve their target blood pressure (BP). To this end, emergence of more...

Descripción completa

Detalles Bibliográficos
Autores principales: Pradhan, Akshyaya, Tiwari, Ashish, Sethi, Rishi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6925743/
https://www.ncbi.nlm.nih.gov/pubmed/31885897
http://dx.doi.org/10.1155/2019/1824621
_version_ 1783481964961988608
author Pradhan, Akshyaya
Tiwari, Ashish
Sethi, Rishi
author_facet Pradhan, Akshyaya
Tiwari, Ashish
Sethi, Rishi
author_sort Pradhan, Akshyaya
collection PubMed
description Hypertension continues to be global pandemic with huge mortality, morbidity, and financial burden on the health system. Unfortunately, most patients with hypertension would eventually require two or more drugs in combination to achieve their target blood pressure (BP). To this end, emergence of more potent antihypertensive drugs is a welcome sign. Angiotensin receptor blockers (ARBs) are cornerstones of hypertension management in daily practice. Among all ARBs, azilsartan is proven to be more potent in most of the head-to-head trials till date. Azilsartan is the latest ARB approved for hypertension with greater potency and minimal side effects. This review highlights the role of azilsartan in management of hypertension in the current era.
format Online
Article
Text
id pubmed-6925743
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-69257432019-12-29 Azilsartan: Current Evidence and Perspectives in Management of Hypertension Pradhan, Akshyaya Tiwari, Ashish Sethi, Rishi Int J Hypertens Review Article Hypertension continues to be global pandemic with huge mortality, morbidity, and financial burden on the health system. Unfortunately, most patients with hypertension would eventually require two or more drugs in combination to achieve their target blood pressure (BP). To this end, emergence of more potent antihypertensive drugs is a welcome sign. Angiotensin receptor blockers (ARBs) are cornerstones of hypertension management in daily practice. Among all ARBs, azilsartan is proven to be more potent in most of the head-to-head trials till date. Azilsartan is the latest ARB approved for hypertension with greater potency and minimal side effects. This review highlights the role of azilsartan in management of hypertension in the current era. Hindawi 2019-11-03 /pmc/articles/PMC6925743/ /pubmed/31885897 http://dx.doi.org/10.1155/2019/1824621 Text en Copyright © 2019 Akshyaya Pradhan et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Pradhan, Akshyaya
Tiwari, Ashish
Sethi, Rishi
Azilsartan: Current Evidence and Perspectives in Management of Hypertension
title Azilsartan: Current Evidence and Perspectives in Management of Hypertension
title_full Azilsartan: Current Evidence and Perspectives in Management of Hypertension
title_fullStr Azilsartan: Current Evidence and Perspectives in Management of Hypertension
title_full_unstemmed Azilsartan: Current Evidence and Perspectives in Management of Hypertension
title_short Azilsartan: Current Evidence and Perspectives in Management of Hypertension
title_sort azilsartan: current evidence and perspectives in management of hypertension
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6925743/
https://www.ncbi.nlm.nih.gov/pubmed/31885897
http://dx.doi.org/10.1155/2019/1824621
work_keys_str_mv AT pradhanakshyaya azilsartancurrentevidenceandperspectivesinmanagementofhypertension
AT tiwariashish azilsartancurrentevidenceandperspectivesinmanagementofhypertension
AT sethirishi azilsartancurrentevidenceandperspectivesinmanagementofhypertension